Harvesting of peripheral blood stem cells (PBSCs) following chemotherapy and G-CSF administration is currently performed for hematological therapies. However, a procedure based on the use of a large quantity of G-CSF is relatively costly. Therefore, we retrospectively compared the effects of two PBSC mobilization procedures in a population with recently diagnosed multiple myeloma. The first procedure consisted of chemotherapy and systematic G-CSF administration (group 1: 24 patients). The second consisted of chemotherapy alone, G-CSF having been administered only in the case of failure of PBSC mobilization or delayed white blood cell (WBC) recovery (group 2: 28 patients). Leukapheresis was performed when WBC recovery reached 1 × 10 9 /l if the peripheral blood CD34 ؉ cell count was over 10/l. Leukapheresis was maintained until a total of 2.5 × 10 6 CD34 ؉ cells/kg was harvested. A significant difference was observed between the two groups only in regard to the median period of WBC recovery (delayed for group 2) and the number of CD34 ؉ cells/kg collected on the first leukapheresis (higher for group 1) but not to the proportion of patients with failure of PBSC collection. Ten group 2 patients, who had insufficient CD34 ؉ cells after WBC recovery or delayed WBC recovery, received G-CSF which resulted in sufficient PBSC harvesting in nine. To obtain a sufficient CD34 ؉ cell level, the patients without systematic G-CSF administration had more leukaphereses (2.1 vs 1.5) but the mean consumption of G-CSF per patient was eight times less than in the other group. Nonsystematic use of G-CSF before WBC recovery or preferentially its introduction just after, could be an interesting economical alternative in PBSC mobilization but should be assessed by a prospective controlled study of cost/efficacy.
Harvesting of peripheral blood stem cells (PBSCs) with cell separators is currently performed for hematological therapies. The products of leukapheresis are used successfully to support recovery from myeloablative regimens in the treatment of malignant diseases such as multiple myeloma.
1-3 However, a minimal PBSC level must be infused for correct hematological reconstitution. 4 This optimal level is obtained after the white blood cell (WBC) recovery which follows intravenous chemotherapy treatment and an immediately subsequent administration of hematopoietic growth factor. 5, 6 However, a procedure based on the use of a large quantity of G-CSF is relatively costly, and the use of G-CSF only in the case of insufficient PBSC mobilization during WBC recovery could constitute an alternative. For this reason, we retrospectively compared the effects of two PBSC mobilization procedures in two homogenous populations of patients with recently diagnosed multiple myeloma: the first procedure consisted of chemotherapy and G-CSF, the second consisted of chemotherapy alone, with G-CSF performed only in the case of failure of PBSC mobilization or delayed white blood cell recovery.
Patients and methods

Protocol of the study
PBSC collections were performed in 52 recently diagnosed multiple myeloma patients having stage II or III disease according to the classification of Salmon and Durie. Before the PBSC mobilization procedure, patients had received no or only one course of a conventional chemotherapy regimen or local radiotherapy. The PBSC mobilization procedure consisted of one course of a reinforced CHOP regimen (C2H2OP), including doxorubicin 90 mg/m 2 day 1, cyclophosphamide 1500 mg/m 2 day 1, vincristine 2 mg day 1 and prednisone 80 mg/m 2 days 1-5. All patients had a blood count every other day after the end of chemotherapy until WBC recovery. Leukapheresis was performed when the WBC recovery reached 1 × 10 9 /l or more if the peripheral blood CD34 ϩ cell count was over 10/l. Daily leukapheresis was maintained until a minimal count of 2.5 × 10 6 CD34 ϩ cells/kg was harvested, this value being the minimum required for successful engraftment. 4 The 52 patients were subdivided into two groups: Group 1 included 24 patients (mean age: 57 (41-66) years, 12 were male), in whom PBSC mobilization was performed by chemotherapy followed immediately by systematic subcutaneous G-CSF administration (5 g/kg/day). G-CSF was continued daily until the CD34 ϩ cell count (performed every other day during a 6-day period) exceeded 10/l. 7 If this level was not reached by the third CD34 ϩ cell count, PBSC collection was not performed. For the other patients, G-CSF was administered daily until the last leukapheresis. Group 2 included 28 patients (mean age: 51 (36-62) years, 10 were male), in whom PBSC mobilization was performed by chemotherapy alone, except in two circumstances: first, if PBSC mobilization was insufficient (ie CD34 ϩ cell count lower than 10/l when the WBC count reached 1 × 10 9 /l or more); second, if WBC recovery was not reached at day 15 post-chemotherapy. In both cases, G-CSF was given (5 g/kg/day) and a CD34 ϩ cell count was undertaken 2 days later. As for the group 1 patients, G-CSF was continued daily until the CD34 ϩ cell count (performed every other day during a 6-day period) was higher than 10/l. If this level was not reached by the third CD34 ϩ cell count, PBSC collection was not performed.
The following parameters were determined in all patients: the period before WBC recovery as defined by a WBC count у1 × 10 9 /l; the number of CD34 ϩ cells/kg collected on the first leukapheresis; the number of leukapheresis procedures necessary to collect 3 × 10 6 CD34 ϩ cells/kg; the number of patients in whom a failure of PBSC collection was observed; G-CSF consumption as estimated through the number of daily injections; all CD34 ϩ cell counts harvested by leukapheresis. CD34 ϩ cell quantification was performed as previously described by fluorescence analysis. 4 Briefly, 1 × 10 6 mononuclear cells were incubated for 30 min at 4°C with the fluorescein isothiocyanate-conjugated monoclonal antibody HPCA-2 (CD34) (Becton Dickinson, Le Pont-de-Claix, France). Cells were quantified by FACSscan.
Documented infections and hospitalization days for septic complications were recorded. Hematological reconstitution was reported for the 13 and 16 patients of groups 1 and 2, respectively, who had an autograft following intensification therapy. No G-CSF administration was provided after the autograft.
Statistical analysis
The Fisher exact test and non-parametric Wilcoxon test were used to analyze the failure in PBSC collection and the quantitative parameters as the WBC recovery, the CD34 ϩ cells harvested, the number of leukapheresis performed, respectively. Table 1 gives, for each group, the median period of WBC recovery following chemotherapy, the number of CD34ϩ cells/kg collected on the first leukapheresis product, the number of leukapheresis procedures necessary to collect 2.5 × 10 6 CD34 ϩ cells/kg and the proportion of patients in whom a failure in PBSC collection was observed. A significant difference was observed between the two groups only for the first two parameters. Table 2 gives the G-CSF consumption as estimated through the number of daily injections.
Results
Total CD34 ϩ counts harvested by leukapheresis were 6.9 and 3.7 × 10 6 /kg per patient in groups 1 and 2, respectively (P = 0.04).
Ten group 2 patients (36%), who had insufficient CD34 ϩ cells after WBC recovery or too delayed WBC recovery, received G-CSF between the 13th and 18th days (median: 15th day). The median number of G-CSF injections per patient was 3 (3-6). The median CD34 ϩ cell count (× 10 6 /kg) collected during the first leukapheresis procedure was 0.92. The median number of leukaphereses necessary to obtain 2.5 × 10 6 CD34 ϩ cells/kg was 2 (1-3). Among these 10 individuals, G-CSF administration allowed sufficient PBSC harvesting in nine.
The number of documented infections was equivalent for both groups. The median hospitalization period for septic complications was identical for the two groups (data not Table 2 Parameters of G-CSF and leukapheresis consumption in the two groups of the study
Group 1 Group 2 Chemotherapy and systematic Chemotherapy without systematic G-CSF administration G-CSF administration
No. patients 24 28
Total G-CSF injections 230 33
Mean number of G-CSF injections per patient (range) 9.5 (7-18) 1.2 (0-6)
Number of leukapheresis 37 60
Mean number of leukapheresis per patient (range) 1.5 (1-3) 2.1 (1-4) (11) (12) (13) (14) (15) (16) (17) shown). No death was observed. Short-term hematological reconstitution following the pretransplant regimen plus PBSC transfusion was identical for the two groups (Table  3) .
Discussion
PBSC autografting has improved the prognosis of multiple myeloma. 8 Usually, PBSC are obtained during WBC recovery by leukapheresis performed after stem cell mobilization by chemotherapy and hematopoietic growth factor administration. The G-CSF has two roles: to reduce the duration of neutropenia and to increase PBSC mobilization. To our knowledge, no controlled study has provided evidence that a significant difference in mortality could be linked to reduction of the duration of post-chemotherapy neutropenia. [9] [10] [11] Moreover, no randomized prospective study has been performed to determine the best schedule of G-CSF in PBSC mobilization.
Since the systematic use of G-CSF for PBSC collection after chemotherapy is costly, we compared two strategies: first, the systematic administration of G-CSF after the administration of chemotherapy; second, G-CSF only in case of delayed WBC recovery and/or poor PBSC mobilization. In our comparative study, we observed that the proportion of failures in PBSC collection was equivalent in both groups. To obtain a sufficient CD34 ϩ cell level, the patient group without systematic G-CSF administration required more leukapheresis but had a mean consumption of G-CSF per patient that was eight times less than in the other group. Indeed, G-CSF was given only to a third of patients without systematic G-CSF and with very limited requirements (mean number of injection for the 10 patients: 3.3). These results suggest that G-CSF could be introduced during or immediately after WBC recovery for all patients without loss of CD34 ϩ cells harvested rather than being introduced immediately after chemotherapy. This suggestion is supported by the fact that after chemotherapy the number of high affinity receptors for G-CSF expressed by mature myeloid precursors and neutrophil cells is reduced and clearance of the growth factor decreases. In these circumstances, a low dose of G-CSF is sufficient to maintain adequate serum levels for PBSC mobilization. 12 On the contrary, after WBC recovery, G-CSF clearance increases and growth factor administration is required to maintain or correct the level of mobilization.
In our series, the duration of neutropenia in the group without systematic administration of G-CSF was not marked by a more frequent occurrence of sepsis and death. However, the patients included in our study had received no previous intensive therapies which would be liable to compromise PBSC mobilization. 13, 14 In patients with a large amount of previous cumulative therapy, systematic G-CSF administration following chemotherapy probably reduces risk of insufficient PBSC mobilization.
Such a strategy has been used to collect enough PBSC for one graft. Of course, if several courses of therapeutic intensification followed by stem transfusion are planned, a higher CD34 ϩ cell count is required for harvesting. In these conditions, the use of high doses of G-CSF may be considered.
An alternative strategy could consist of using G-CSF alone without chemotherapy. However, such a strategy is less efficient than chemotherapy plus G-CSF for PBSC harvesting and significantly increases the cost of the procedure. 15 Moreover, the tumor load in leukapheresis products from patients with multiple myeloma is lower after a procedure consisting of chemotherapy plus G-CSF than after the use of G-CSF alone. 16 In conclusion, the non-systematic use of G-CSF early after chemotherapy (before WBC recovery) could be an interesting alternative of PBSC mobilization for patients without high-dose cumulative previous therapy. In contrast, G-CSF introduction during or imediately after WBC recovery could optimize PBSC harvesting and reduce the cost of the total procedure without negative consequences for patients. These hypotheses should be assessed by a prospective controlled study of cost/efficacy.
